On December 1st, the interdisciplinary educational project “Legislative and regulatory environment in the pharmaceutical industry” has been launched in Russia at the Faculty of Law of the National Research University “Higher School of Economics (HSE)”, that was organized involving the NovaMedica, a portfolio company of ROSNANO, and a number of other pharmaceutical companies and law firms. This is the first law course in Russia, where students will receive specialized legal knowledge considering the specificity of the pharmaceutical industry.
“Investment in the development of knowledge and skills to improve the legal environment is just as important for the Russian pharmaceutical industry, as the investment in the setting of new capacities”, said Alexander Kuzin, Managing Director “NovaMedika”.
The program is based on a combination of two approaches: the creation of a business vision of the listeners, for which is dedicated not less than 30% of the classes, and the development of applicable pharmaceutical specific legal skills. The course program includes lectures on a wide range of current trends in the industry: R&D, promotion of products, quality control, etc. The course is designed for 55 students and open to the unenrolled students. The training program will last 8 months. At the end of the course, the students will write memoranda on pressing issues of the pharmaceutical industry regulation.
The initiators and leaders of the project are Alexander Panov, the expert at the Center for pharmaceuticals and biotechnology regulatory environment studies at the Law Department of the HSE and “NovaMedika” company’s lawyer, as well as Dmitry Mazaev, Deputy dean of the Law Department of the HSE, and Roman Shabrov, Partner of Brace law firm. In the near future, the course organizers expect to create a master’s program on its basis.
The pilot project of the course has been successfully tested in the academic period in 2015-2016 years, its graduates have already used the gained knowledge in the Russian pharmaceutical industry. In the current academic year, the course has expanded and new partners have appeared: the pharmaceutical companies Novartis, Sanofi, Sentiss and others, as well as the leading legal companies Pepeliaev Group, Hogan Lovells and others.